| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2170527 | Cytokine & Growth Factor Reviews | 2015 | 7 Pages |
Abstract
Upregulation of IGF2 occurs in both childhood and adult malignancies. Its overexpresssion is associated with resistance to chemotherapy and worse prognosis. IGF2 promoter usage is developmentally regulated; however, malignant tissues are characterized by re-activation of the fetal IGF2 promoters, especially P3. In this review, we describe the mechanisms of IGF2 signaling and regulation in normal and malignant tissues and their clinical implications.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Jurriaan Brouwer-Visser, Gloria S. Huang,